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Background: Little is known about the relative contribution of long-term glycemic variability to the risk of macrovascular com-
plications in type 2 diabetes. This study was conducted to evaluate the effect of A1C variability on the progression of carotid ar-
tery intima-media thickness (IMT) in type 2 diabetic patients. 
Methods: Among type 2 diabetic patients who visited Hallym University Sacred Heart Hospital from March 2007 to September 
2009, 120 patients who had carotid artery IMT measured annually and A1C checked every three months for at least one year 
were analyzed. Individual A1C variability was defined as the standard deviation (SD) of five A1C levels taken every three months 
for approximately one year. Change in IMT was defined as an increase in IMT on follow-up measurement. The association be-
tween the SD of A1C and changes in IMT was evaluated.
Results: With greater A1C variability, there was a greater increase in the mean IMT (r = 0.350, P < 0.001) of the carotid artery. 
After adjusting for confounding factors that may influence IMT, A1C variability was significantly associated with the progression 
of IMT (r = 0.222, P = 0.034). However, the SD of A1C was not a significant independent risk factor for the progression of IMT 
in multiple regression analysis (β = 0.158, P = 0.093).
Conclusion: Higher A1C variability is associated with IMT progression in type 2 diabetic patients; however, it is not an indepen-
dent predictor of IMT progression. Overall glycemic control is the most important factor in the progression of IMT.
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INTRODUCTION
Diabetes is characterized by a high incidence of accelerated 
atherosclerosis [1]. Although researchers have examined the 
roles of numerous factors involved in the macrovascular com-
plications of diabetes, a precise judgment of their individual 
contributions remains challenging [2]. Diabetic complications 
are mainly dependent on dysglycemia [1,3], and diabetes is 
characterized by both sustained chronic hyperglycemia and 
acute glucose fluctuation, both of which lead to diabetic com-
plications [4].
  Similar glycemic levels can be generated by different glucose 
profiles [4,5]. Among patients with similar glycemic levels, those 
with larger glucose variability might be at greater risk for devel-
oping chronic complications [4-6]. There is firm evidence that 
postprandial glycemia is a stronger risk factor for the develop-
ment of macrovascular complications than are fasting or pre-
prandial concentrations [7,8]. Therefore, diabetic manage-
ment primarily focuses on the attenuation of glycemic excur-
sions following meals with the belief that glycemic control re-
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duces the risk of cardiovascular disease [9]. However, little is 
known about the relative contribution of long-term glycemic 
variability to the risk of developing macrovascular complica-
tions in type 2 diabetes.
  Intima-media thickness (IMT) is a well-described surrogate 
marker for cardiovascular risk [10-13]. In cross-sectional anal-
yses, increased IMT was correlated with myocardial infarction 
and stroke [14]. 
  Understanding the risks of long-term glycemic variability is 
fundamental to the management of diabetes. In this study, we 
evaluated the relationship between A1C variability and the pro-
gression of IMT in type 2 diabetic patients.
METHODS 
Subjects 
Among type 2 diabetic patients who visited Hallym University 
Sacred Heart Hospital from March 2007 to September 2009, 
patients who had annual carotid artery IMT measurements 
and who had their A1C level checked every three months for 
at least one year were enrolled. We analyzed data from patients 
who had visited the clinic on more than three consecutive oc-
casions prior to enrollment since biochemical parameters such 
as A1C show marked changes after initial treatment (n = 120).
  Exclusion criteria were type 1 diabetes; history or clinical 
evidence of coronary artery disease or cerebral or peripheral 
vascular disease; renal dysfunction (defined as creatinine blood 
level ≥ 2.0 mg/dL); hepatic dysfunction (defined as alanine ami-
notransferase and/or aspartate aminotransferase blood level ≥ 3 
× the upper normal limit); use of glucocorticoids; pregnancy; 
severe concomitant disease such as cancer, infection, Cushing’s 
syndrome, acromegaly, or any other disorder likely to alter gly-
cemia; primary hypercholesterolemia, hypothyroidism or hy-
perthyroidism; use of any hormonal drugs; and alcoholism or 
drug abuse. 
  Hypertension was defined as systolic blood pressure of at least 
140 mm Hg and/or a diastolic blood pressure of at least 90 mm 
Hg, use of antihypertensive drugs, or a combination of these 
parameters. Dyslipidemia was defined as an low density lipopro-
tein cholesterol (LDL-C) level ≥ 100 mg/dL or an high density 
lipoprotein cholesterol (HDL-C) level < 40 mg/dL for men, < 50 
mg/dL for women, or the use of lipid-lowering drugs. Protei-
nuria was defined as a 24 hour albuminuria ≥ 30 mg/day. 
Retinopathy was defined by at least one retinal microaneurysm 
with or without hemorrhages, venous beading, soft exudates, 
or intraretinal microvascular abnormalities. Neuropathy was 
defined as the presence of bilateral pain and paresthesias in the 
lower limbs or the presence of a positive finding on the current 
perception threshold test. The protocol was approved by the 
Ethics Committee of Hallym University, and informed written 
consent was obtained from each participant.
Clinical characteristics
Height, weight, and blood pressure were measured for each par-
ticipant, with blood pressure measured twice in a sitting posi-
tion using a sphygmomanometer at the level of the heart. The 
average of the measurements was used as the reference data. 
Body weight and height were measured in the morning with 
participants wearing light clothing. Body mass index (BMI) was 
calculated as body weight in kilograms divided by height in 
meters squared (kg/m
2). Waist circumference was determined 
using a measuring tape placed midway between the lowest rib 
and the iliac crest, with the participant standing on a flat floor 
with feet 30 cm apart.  
Biochemical characteristics 
Blood samples were collected from subjects after more than 10 
hours of fasting. A1C was determined using high-performance 
liquid chromatography (Variant II; Bio-Rad, Hercules, CA, USA). 
Plasma glucose levels were measured immediately after sam-
pling with an autoanalyzer, using the hexokinase method (Hi-
tachi 747; Roche, Montclair, NJ, USA). Serum insulin levels 
were determined using an INS-IRMA Kit (BioSource Europe 
S.A., Nevelles, Belgium), and serum total cholesterol and HDL-
C were measured using a direct enzymatic method (Hitachi 
747; Daiichi, Tokyo, Japan). Serum triglyceride levels were mea-
sured using an enzymatic colorimetric method (Hitachi 747; 
Roche, Japan/Germany), and LDL-C was calculated using the 
Friedewald formula, i.e., total cholesterol - {(triglyceride/5) + 
HDL-C}. Insulin resistance was estimated after fasting using the 
homeostasis model assessment method (HOMA-IR): HOMA-
IR = fasting insulin (μU/mL) × fasting plasma glucose (mmol/L) / 
22.5. Individual A1C variability was defined as the standard 
deviation (SD) of five A1C levels taken every three months for 
about one year.
Carotid artery IMT
We measured IMT at baseline and after 12 months of follow-up. 
Change in IMT was defined as an increase in IMT on the fol-
low-up measurement. IMT was measured by one examiner us-176
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ing a B-mode ultrasound with an 8 MHz linear probe (Sequoia 
C512; Siemens, Munich, Germany). IMT was measured at three 
points of the common carotid artery 1 cm proximal to the bi-
furcation, and the mean value of six measurements from the 
right and left carotid arteries was used. Reproducibility was fur-
ther tested, and the day-to-day coefficient of variation was 4.5% 
for carotid IMT measurements. Moreover, when calcifications 
or plaques showed heterogeneity in the area of IMT determi-
nation, measurements were performed proximally in order to 
exclude plaques.
Statistics
Descriptive statistics are presented as mean values ± SD. Sub-
jects were divided into three groups according to the individual 
A1C variability (SD of five A1C levels taken every three months 
for about one year).
  Comparisons of clinical and physiological characteristics of 
each group were performed using ANOVA. 
  Partial correlation analysis was used to assess the significance 
of the relationship between A1C variability and the progression 
of carotid IMT after controlling for age, gender, diabetes dura-
tion, menopause status, smoking status, hypertension status, 
dyslipidemia status, albuminuria status, BMI, waist circumfer-
ence, blood pressure, LDL-C level, HDL-C level, HOMA-IR, 
fasting and postprandial glucose, mean A1C, baseline A1C, 
and use of medications likely to alter IMT (thiazolidinediones, 
statins, calcium channel blockers, angiotensin converting en-
zyme inhibitors, angiotensin receptor blockers, anti-platelet 
agents). The inclusion of the controlling factors in partial cor-
relation analysis removed the possibility of their contributions 
to the outcome [15].
  Moreover, independent risk factors for progression of IMT 
were identified using multiple linear regression analysis. We 
selected all of the variables which showed a potential associa-
tion (P < 0.20) with the progression of IMT in the correlation 
analysis [16]. We also entered known cardiovascular risk factors 
such as gender, BMI, diabetes duration, blood pressure, base-
line IMT, and lipid levels into the model.
  All statistical analysis was performed using SPSS for Windows 
11.5 (SPSS Inc., Chicago, IL, USA), and P values less than 0.05 
were considered to be statistically significant.
RESULTS 
 
Table 1 shows the baseline clinical and biochemical character-
Table 1. Baseline clinical and biochemical data  
Characteristics Mean ± SD
Gender, F/M, n (%) 54 (45)/66 (55)
Age, yr   55.7 ± 7.4
Height, cm 162.8 ± 9.4
Weight, kg   66.5 ± 9.3 
BMI, kg/m
2   25.2 ± 3.6 
Waist circumference, cm   89.5 ± 7.7
Diabetes duration, yr     8.7 ± 6.1
SBP, mm Hg   126.4 ± 13.6
DBP, mm Hg   77.0 ± 7.9
A1C, %     7.8 ± 1.5 
Fasting plasma glucose, mg/dL   144.0 ± 45.5
Postprandial plasma glucose, mg/dL   213.1 ± 87.0
Total cholesterol, mg/dL   168.3 ± 45.4
Triglyceride, mg/dL   129.8 ± 56.1 
HDL-C, mg/dL     50.4 ± 13.2
LDL-C, mg/dL     89.0 ± 38.2 
C-peptide, ng/mL     1.98 ± 1.04 
HOMA-IR       2.3 ± 0.82
Mean IMT, mm     0.85 ± 0.12
Diagnosis of dyslipidemia, n (%)   86 (71.7)
Diagnosis of hypertension, n (%)   77 (64.2)
Diagnosis of albuminuria, n (%)   28 (23.3)
Diagnosis of neuropathy, n (%)   17 (14.2)
Diagnosis of retinopathy, n (%)   14 (11.7)
Menopause   40 (33.3)
Smoking, n (%)
   Never
   Previous
   Current
  88 (73.3)
  18 (15.0)
  14 (11.7)
Use of RAS inhibition, n (%)   75 (62.5)
Use of calcium channel blocker, n (%)   32 (26.7)
Use of statin, n (%)   89 (74.2)
Use of anti-platelet agents, n (%) 105 (87.5)
Use of sulfonylurea, n (%)   69 (57.5)
Use of metformin, n (%)   83 (69.2)
Use of thiazolidinedione, n (%)   26 (21.7)
Use of meglitinide, n (%)   83 (69.2)
Use of alpha-glucosidase inhibitor, n (%)   17 (14.2)
Use of insulin, n (%)   23 (19.2)
SD, standard deviation; BMI, body mass index; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; HDL-C, high density lipopro-
tein cholesterol; LDL-C, low density lipoprotein cholesterol; HOMA-
IR, homeostasis model assessment–insulin resistance; IMT, intima-
media thickness; RAS inhibition, renin-angiotensin system inhibition 
with ACE inhibitor or angiotensin type 1 receptor antagonist.177
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Fig. 1. Changes in A1C levels during the 12 months. (A) All subjects. (B) Groups according to A1C variability. Group 1, low A1C 
variability group; Group 2, intermediate A1C variability group; Group 3, high A1C variability group. 
Table 2. Clinical and biochemical data according to A1C variability
A1C variability (tertiles) P  
value Group I (n = 40) Group II (n = 40) Group III (n = 40)
Age, yr 57.3 ± 7.5 56.3 ± 6.7 53.5 ± 7.5 0.056
Height, cm 162.5 ± 8.5 161.4 ± 8.7 164.4 ± 10.9 0.357 
Weight, kg 65.7 ± 8.6 65.7 ± 10.0 68.1 ± 9.4 0.412 
BMI, kg/m
2 24.9 ± 3.2 25.2 ± 3.5 25.4 ± 4.1 0.859
Waist circumference, cm 88.8 ± 7.0 89.4 ± 8.8 90.3 ± 7.3 0.693 
Diabetes duration, yr 7.7 ± 5.2 9.3 ± 7.0 8.9 ± 5.9 0.463
SBP, mm Hg 126.9 ± 12.9 123.8 ± 15.0 128.7 ± 12.6 0.259 
DBP, mm Hg 77.0 ± 8.0 75.0 ± 6.7 79.2 ± 8.4  0.060
A1C at baseline, % 6.7 ± 0.5 7.5 ± 1.2
a 9.3 ± 1.3
a,c 0.000
Mean A1C, % 6.7 ± 0.4 7.3 ± 1.0
a      8.4 ± 1.0
a,c 0.000
   SD of A1C (min–max) 0.20 ± 0.07 (0.08 to 0.29) 0.42 ± 0.11
a (0.29 to 0.62) 1.01 ± 0.30
a,c (0.66 to 1.83) 0.000
Fasting plasma glucose, mg/dL 126.3 ± 36.8 144.1 ± 33.5
b 161.7 ± 56.5
b 0.002 
Postprandial plasma glucose, mg/dL 186.2 ± 77.5 216.1 ± 89.0 237.2 ± 88.3
b 0.030 
Total cholesterol, mg/dL 167.6 ± 47.0 156.3 ± 27.1 181.0 ± 55.0 0.050
Triglyceride, mg/dL 128.2 ± 63.2 124.9 ± 51.0 136.4 ± 54.5 0.648
HDL-C, mg/dL 51.8 ± 12.5 49.6 ± 15.0 49.8 ± 12.3 0.726
LDL-C, mg/dL 85.8 ± 37.0 81.7 ± 26.3 99.7 ± 47.0 0.086
C-peptide, ng/mL 2.1 ± 1.1 1.9 ± 1.1 2.0 ± 0.9 0.819 
HOMA-IR 2.2 ± 0.9 2.2 ± 0.8 2.4 ± 0.7 0.433 
Mean IMT at baseline, mm 0.82 ± 0.11 0.85 ± 0.09 0.89 ± 0.12
b 0.043
Data are means ± standard deviation (SD). Group I, low A1C variability group; Group II, middle A1C variability group; Group III, high A1C 
variability group. A1C variability status was defined according to the SDs of the means of five A1C levels taken every three months for about 
one year. Results were calculated using an ANOVA test. 
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C; high density lipoprotein cholesterol; LDL-C, low 
density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-insulin resistance; IMT, intima-media thickness.
aSignificantly different compared to Group I (P < 0.001), 
bSignificantly different compared to Group I (P < 0.05), 
cSignificantly different com-
pared to Group II (P < 0.001).178
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istics of the subjects. The mean baseline IMT of the subjects was 
0.85 ± 0.12 mm, and the mean progression of IMT was 0.04 ± 
0.09 mm. The mean follow-up period was 369.7 ± 15.2 days.
Change of A1C over 12 months
Fig. 1A shows the changes in A1C level at three month intervals, 
illustrating that the levels gradually decreased over 12 months. 
Fig. 1B demonstrates the changes in glucose level in the three 
groups with different A1C variabilities over a 12 month period. 
The group with the highest A1C variability had the highest base-
line A1C and experienced the greatest decrease in plasma glu-
cose level, while the group with the lowest A1C variability had 
the lowest baseline A1C and had stable plasma glucose levels 
over the study period (Table 2, Fig. 1B).   
Clinical and biochemical characteristics according to A1C 
variability 
Tables 2, 3 demonstrate the clinical and biochemical character-
istics of the three groups with different A1C variabilities. There 
were no differences in age, body size, duration of diabetes mel-
litus, blood pressures, lipid profiles, insulin secretory function, 
insulin resistance, diagnoses of concurrent diseases, or diabetes-
related drug history among the groups. However, the group 













Gender, F/M 17/23 21/19 16/24 0.493
Diagnosis of dyslipidemia, n  32 34 29 0.082
Diagnosis of hypertension, n 26 24 27 0.776
Diagnosis of albuminuria, n   7 13   9 0.247
Diagnosis of neuropathy, n   8   6   3 0.291
Diagnosis of retinopathy, n   4   5   5 0.913
Menopause, n 14 16 10 0.350
Smoking status 0.623
   Never 27 32 29
   Previous   7   3   4
   Current   6   5   7
A1C variability status was defined as a standard deviations of the means 
of five A1C levels taken every three months for about one year. Results 
were calculated using the chi-square test. 
Group I, low A1C variability group; Group II, middle A1C variability 
group; Group III, high A1C variability group.
Table 4. Multiple regression analysis of the progression of carot-
id IMT 
Independent variable β P value
Age, yr 0.110 0.394 
Gender (F = 0, M = 1) -0.160 0.108
BMI, kg/m
2 0.077 0.426
Diabetes duration, yr -0.071 0.474
SBP, mm Hg -0.023 0.864
DBP, mm Hg 0.098 0.480
Baseline IMT, mm 0.018 0.853
A1C, % 0.129 0.658
Mean A1C, % 0.314 0.043
SD of A1C 0.158 0.093
Fasting blood glucose, mg/dL 0.298 0.046
Postprandial plasma glucose, mg/dL 0.253 0.095
HDL-C, mg/dL -0.067 0.485
LDL-C, mg/dL 0.009 0.924
Triglyceride, mg/dL -0.153 0.107
Menopause (No = 0, Yes = 1) 0.018 0.906
Use of anti-platelet agents (No = 0, Yes = 1) -0.237 0.113
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; SD, standard deviation; HDL-C; high density lipo-
protein cholesterol; LDL-C, low density lipoprotein cholesterol; IMT, 
intima-media thickness. 
Fig. 2. Correlation between A1C variability and progression 
of IMT of the carotid artery. r = 0.350, P < 0.001 (r = 0.222, P = 
0.034 after adjusting for confounding factors). IMT, intima-
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with the greatest A1C variability had the highest baseline and 
mean A1C level compared to those of the other groups (Table 
2). The A1C variability was also closely related to the mean A1C 
of all patients (r = 0.676, P < 0.001).   
A1C variability and progression of IMT
We found that, with greater A1C variability, there was a greater 
increase in the IMT (r = 0.350, P < 0.001) of the carotid artery 
(Fig. 2). Although this relationship weakened after adjusting 
for confounding factors that can influence the progression of 
IMT, it remained statistically significant (r = 0.222, P = 0.034, 
Fig. 2).
Multiple regression analysis of the progression of IMT
In order to evaluate factors that influence the progression of 
IMT, multiple regression analysis was performed. Mean A1C 
(β = 0.314, P = 0.043) and fasting plasma glucose (β = 0.298, P = 
0.046) were found to be independent predictors of the progres-
sion of IMT (Table 4). However, the SD of A1C was not a sig-
nificant independent risk factor for the progression of IMT in 
multiple regression analysis (β = 0.158, P = 0.093).
DISCUSSION 
This study demonstrates that the long-term variability in A1C 
level has no significant influence on the progression of carotid 
atherosclerosis in patients with type 2 diabetes. Although A1C 
variability over 12 months was found to be associated with the 
progression of IMT, overall glycemic control is the most impor-
tant factor in the progression of IMT. 
  Recently, Kilpatrick et al. [5] concluded that A1C variability 
may be an additional risk factor for the development of micro-
vascular complications in type 1 diabetic patients. Previously, 
they had reported that daily glucose variability, as measured on 
a quarterly eight-point glucose profile, was not associated with 
the development or progression of retinopathy or nephropathy 
[17]. It has also been suggested that A1C variability might play 
an important role in the development of long-term macrovas-
cular complications in type 1 diabetes [6]. 
  Few studies have been conducted to evaluate the relation-
ship between glycemic variability and the development of mac-
rovascular complications in type 2 diabetics, the major cause 
of diabetic mortality. Previously, Muggeo et al. [18] reported 
that long-term instability in fasting plasma glucose concentra-
tions was an independent predictor of cardiovascular-related 
five-year mortality in elderly type 2 diabetic patients with a mean 
age of 80 years and a short life expectancy. Subsequently, they 
confirmed these result over a period of 10 years in type 2 dia-
betics with an age range of 56-74 years [17]. The relationship 
between the variability of fasting plasma glucose and cardiovas-
cular mortality could result from more frequent hypoglycemia, 
which predisposes patients to adverse outcomes [19,20]. 
  When patients are exposed to hyperglycemia more frequent-
ly and for longer periods, more hyperglycemia-related compli-
cations are likely to develop because frequent exposure to hy-
perglycemia leads to excessive protein glycation and increased 
oxidative stress [4]. Also, there is data on the effect of glycemic 
changes on free radical production [21]. Moreover, sustained 
hyperglycemia has lasting effects, and patients are at higher risk 
for complications [22,23]. Therefore, the harmful effect of gly-
cemic variability may be mediated through a mechanism sim-
ilar to that underlying “metabolic memory” [22,24]. 
  It remains unclear whether long-term glucose variability 
(week-to-week, as measured by A1C) has a similar influence 
on the development or progression of macrovascular compli-
cations in type 2 diabetics to that of short-term glucose insta-
bility (day-to-day, as measured by fasting plasma glucose). Our 
study demonstrates that long-term glucose variability, measured 
by A1C variability, has no significant influence on the progres-
sion of carotid atherosclerosis in patients with type 2 diabetes. 
Therefore, we conclude that A1C variability has no influence 
on the development of cardiovascular events. Instead of A1C 
variability, overall glycemic control was revealed to be the im-
portant factor in determining the progression of carotid ath-
erosclerosis in type 2 diabetes. 
  In our study, there are several possible reasons that A1C vari-
ation itself was not revealed as an independent risk factor for 
the progression of atherosclerosis. First, this study was conduct-
ed on a relatively low-risk group for cardiovascular diseases (no 
past history of cardiovascular diseases, relatively good glucose 
control state at baseline, limited lipid and blood pressure prob-
lems, and a small number of smokers). Therefore, the progres-
sion of atherosclerosis in this group may have been slow. More-
over, we did not exclude patients receiving medications likely 
to alter IMT (statins, ACE inhibitors, angiotensin receptor block-
ers, and anti-platelet agents). Finally, 12 months is a relatively 
short period in which to assess meaningful progression of ca-
rotid atherosclerosis.
  In our study, regression of IMT was found in 28 subjects. 
These patients had a shorter duration of diabetes (7.1 ± 4.1 vs. 180
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9.1 ± 6.5 year, P = 0.049) and a lower mean A1C level (7.1 ± 0.9 
vs. 7.8 ± 1.1%, P = 0.020) compared to those of subjects with 
progression of IMT. These results suggest that diabetic patients 
of long duration and poor glycemic control are prone to athero-
sclerosis development [15]. 
  Frequent hypoglycemia predisposes patients to cardiovascu-
lar events in type 2 diabetes [20]. The stability of fasting plasma 
glucose seems to be protective and variability seems to be harm-
ful. Moreover, postprandial glucose is a predictor of cardiovas-
cular disease and its measurement is the other component of 
glycemic variability [25,26]. Change in IMT was significantly 
correlated with change in postprandial glucose rather than that 
of fasting glucose [9]. A1C is a standard clinical assessment of 
glycemia and is the basis of most data relating glycemic control 
to diabetic complications [27,28]. A1C reflects mean blood glu-
cose levels including both fasting and postprandial glucose lev-
els [25] and is not affected by glycemic instability [29]. There-
fore, it is possible that A1C variability is not a sensitive measure 
for detecting the effects of hypoglycemia. 
  There is a tendency for greater A1C variability in subjects 
with poor glycemic control, and our study showed a strong cor-
relation between A1C variability and baseline A1C as well as 
mean A1C over 12 months. After adjusting for glucose level, 
the correlation between A1C variability and IMT progression 
was attenuated. 
  We analyzed subjects with poor glycemic control (n = 40). As 
a result, the correlation between A1C variability and the pro-
gression of IMT was stronger than that of all subjects (r = 0.413, 
P = 0.008). Although this relationship was weakened after ad-
justing for confounding factors that can influence the progres-
sion of IMT, it remained statistically significant (r = 0.329, P = 
0.012). However, in multiple regression analysis, A1C variabil-
ity was not a significant independent risk factor for the progres-
sion of IMT (β = 0.256, P = 0.254). 
  In our study, glycemic status was a significant determining 
factor for the progression of IMT in type 2 diabetic patients. 
This finding indicates that blood glucose control may play the 
principal role in interventions to inhibit an increase of IMT in 
type 2 diabetics. Although overall glycemic control is the most 
important factor in the progression of IMT, this does not nec-
essarily mean that glycemic variability is not important in de-
termining outcomes in type 2 diabetes. Global anti-diabetic 
strategy should be aimed first at improving glycemic control 
and then at minimizing the different components of dysglyce-
mia (especially hypoglycemia) in order to avoid excess risk of 
long-term complications [30].  
  There are several possible limitations in our study. First, the 
subjects were not randomly selected and the study was prospec-
tively designed. Moreover, the modifications in individual med-
ication dosages over the 12 months were not reflected in the 
results. 
  In conclusion, relatively long-term variability in A1C levels 
appears to be associated with progression in IMT over 12 months. 
However, the A1C variability itself was not revealed as an inde-
pendent risk factor for the increase in IMT during the 12 month 
study period. Rather than A1C variability, overall glycemic con-
trol was the most important factor for the progression of carotid 
IMT. However, considering the gradual increase in IMT, a lon-
ger follow-up period may be needed to assess A1C variability 
as an independent predictor of progression of atherosclerosis 
in type 2 diabetic patients. 
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